Ketanserin


Generic Medicine Info
Indications and Dosage
Oral
Hypertension
Adult: 20 mg bid; increase to 40 mg bid after 2-4 wk as necessary. May also be given via IV/IM admin.
Hepatic Impairment
Cirrhosis: Reduce dose or increase dosage interval. Severe hepatic impairment: A max of 20 mg bid is recommended.
Special Precautions
2nd or 3rd degree AV block. Patients predisposed to QT prolongation. May impair ability to drive or operate machinery.
Adverse Reactions
Sedation, fatigue, lightheadedness, dizziness, headache, dry mouth, GI disturbances, oedema, ventricular arrhythmias.
Drug Interactions
Hypotensive effects enhanced by diuretics and other antihypertensives.
Potentially Fatal: Increased risk of ventricular arrhythmias including torsade de pointes with antiarrhythmics or drugs that can cause hypokalaemia e.g. diuretics.
Action
Description: Ketanserin is a serotonin antagonist that binds to peripheral serotonin-2 (5HT2) receptors resulting in inhibition of serotonin-induced vasoconstriction, bronchoconstriction and platelet aggregation.
Onset: 1-2 min (IV).
Duration: 30-60 min (IV).
Pharmacokinetics:
Absorption: Rapidly absorbed from the GIT (oral); bioavailability: about 50%. Peak plasma concentrations after 30-120 min.
Distribution: Protein-binding: 95%. May cross the placenta and some is present in breast milk.
Metabolism: Hepatic.
Excretion: Via urine (68% of an oral dose), via faeces (24%), mainly as metabolites.
MIMS Class
Other Antihypertensives
Disclaimer: This information is independently developed by MIMS based on Ketanserin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in